Learning lessons from Pfizer’s $800 million failure

In 2004, Pfizer launched a large Phase 3 trial named ILLUMINATE designed to demonstrate the positive B/R of torcetrapib, an inhibitor of CETPs (cholesterylester transfer proteins) developed to treat high cholesterol. Unfortunately, their decision to take torcetrapib to Phase 3 testing was ultimately catastrophic and extremely costly.